

**LARGE SCALE  
ANALYSIS OF GENE  
EXPRESSION**

**Evolution and Revolution**

**AFTER THE SEQUENCE:  
WHOLE GENOME APPROACHES TO  
BIOLOGICAL QUESTIONS**

**GENE EXPRESSION**


**GENE VARIATION**

**GENE FUNCTION**


## MICROARRAYS PROVIDE A TOOL FOR WHOLE GENOME ANALYSIS

**PRIMARY IMPACT:  
ACCELERATED DISCOVERY AND  
HYPOTHESIS GENERATION**

PUBMED CITATIONS FOR DNA MICROARRAYS



### PUBMED CITATIONS FOR DNA MICROARRAYS



### INCREASE IN FEATURE DENSITY



## **MICROARRAY TERMINOLOGY**

- **Feature--an array element**
- **Probe--a feature corresponding to a defined sequence**
- **Target--a pool of nucleic acids of unknown sequence**

## **POSSIBLE ARRAY FEATURES**



- **Synthetic Oligonucleotides**
- **PCR products from**  
    **Cloned DNAs**  
    **Genomic DNA**
- **Cloned DNA**

## **OLIGONUCLEOTIDE ARRAY DESIGN**

- **Extremely flexible**
  - **3' bias**
  - **full length**
  - **exon specific**
  - **candidate transcripts**
  - **miRNAs**
- **Very high density possible**
- **Requires sequence data**

## **Microarray Manufacture**


- **Printing**





## Microarray Manufacture


- **Printing**
- **Synthesis *in situ***
  - light directed
  - mechanically directed

### LIGHT DIRECTED OLIGONUCLEOTIDE SYNTHESIS









## **MICROARRAY READOUT**

- **Determine quantity of target bound to each probe in a complex hybridization**
- **Must have high sensitivity, low background**
- **High spatial resolution essential**
- **Dual channel capability useful**
- **Fluorescent tags meet these demands**

## **Building Microarrays**

- **Methods are applicable to any organism**
- **Sequenced organisms: oligonucleotides**
- **Unsequenced organisms: cloned DNAs**

## **Building Microarrays**

- **Density depends on specific technology**
- **Pin printing based methods limited to 40-50K**
  - **In situ synthesis: millions**
- **Array design is linked to purpose.**

## **Laboratory Essentials**

- **Arrays**
- **Scanner**
- **Software for processing array image**
  - **Software for data analysis and display**
    - **Bioinformatics collaborator**

## **DNA Microarray Applications**

- **Gene Expression**
- **Comparative Genomic Hybridization**
- **Resequencing (SNPs)**
- **Transcription factor localization**
- **Chromatin/DNA modification**

## Gene Expression Profiling Technologies

- cDNA library sequencing
- Serial analysis of gene expression (SAGE)
- MPSS (massively parallel signature sequencing)
- **Microarray hybridization**



Reports on Microarray Data Quality

Nature Biotechnology

September 2006

## Accessing Expression Data

- Individual Lab and Journal Sites; public databases

GEO

Currently contains  
 expression data on  
 342,783 samples

<http://www.ncbi.nlm.nih.gov/geo/>

## Accessing Expression Data

288524 assays  
 Including 34,264  
 curated, reannotated  
 Assays

<http://www.ebi.ac.uk/microarray-as/ae/>

## Publishing Expression Data

- MIAME standard



Minimum Information about a Microarray Experiment

- Format required by many journals
- Essential for database submissions

<http://www.mged.org/Workgroups/MIAME/miame.html>

## STRATEGIES FOR SIGNAL GENERATION FROM mRNA

- Fluorochrome conjugated cDNA
- Ligand substituted nucleotides with secondary detection (e.g. biotin-streptavidin)
- Radioactivity
- RNA amplification



**Output of Microarray Analysis:**

**expression ratio  
(2 color hybridization)**

**or**

**relative expression level  
(1 color hybridization)**

**Both types of data can be analyzed with  
essentially the same tools.**

**APPLICATIONS OF  
EXPRESSION ARRAYS**

**•Expression profiling**

Power arises from increasing sample number

**•Direct comparisons (Induction)**

Biological system critical

**•Genome Annotation**



## A RECURRING PROBLEM

**Disease Genes**

**Transcription factors**

**Hormones/growth factors**


**Drugs**

**Toxins**

**Infectious agents**

**Physical agents**

**siRNA's**



?????

**Downstream Genes**

•Direct targets

•Indirect targets

## EXPRESSION DATA ANALYSIS

•Large amount of data

Examples: 200 samples x 25000 probes= 5,000,000 data points

•Requires analysis and  
visualization tools

Recent overview of microarray bioinformatics:  
Simon R, Curr Opin Biotechnol. 2008 Feb;19(1):26-9.

## **EXPRESSION DATA ANALYSIS**

- **Check quality of individual experiments**

- **Preprocessing**

- Normalization**

- Remove genes which are not accurately measured

- Remove genes which are similarly expressed in all samples

- **Unsupervised Clustering**

- **Supervised Clustering**

## **Unsupervised Clustering**

How do genes and samples organize into groups?

Powerful method of data display.


Does not prove the validity of groups.

- **Clustered Samples Are Biologically Similar**

- **Clusters of Co-expressed genes**



- **May be functionally related**



- **May be enriched for pathways**




### Matrix of Pearson Correlation Coefficients Distance Map

	RH3	RH4	RH5	RMS13	RH18	RH28	A204	NGP127	TC71	UACC-903	MDA-MB-436	PC3	
ARMS1	0.547	0.606	0.726	0.683	0.634	0.615	0.307	0.39	0.498	0.426	0.417	0.314	
RH3		0.759	0.736	0.69	0.606	0.807	0.444	0.565	0.566	0.391	0.452	0.403	
RH4			0.771	0.778	0.672	0.74	0.441	0.486	0.558	0.488	0.555	0.476	
RH5				0.769	0.667	0.751	0.37	0.486	0.607	0.43	0.532	0.447	
RMS13					0.731	0.746	0.35	0.463	0.582	0.446	0.475	0.404	
RH18						0.703	0.274	0.281	0.549	0.389	0.405	0.36	
RH28							0.417	0.493	0.644	0.479	0.478	0.42	
A204								0.426	0.361	0.398	0.368	0.377	
NGP127									0.352	0.241	0.371	0.368	
TC71										0.46	0.456	0.472	
UACC-903											0.507	0.538	
MDA-MB-436												0.662	
PC3													0.662





## CLUSTERING GENES AND SAMPLES







Perou et al. Nature 2000 406:747

## Supervised Clustering

What genes distinguish samples in selected groups from each other?

- Choice of groups can be based on any known property of the samples.
- Many possible underlying methods: t-test or F-statistic frequently used.
- Output includes ranked gene list.
- Leads to the development of classifiers which can be applied to unknown samples.
- Must address the problem of false discovery due to multiple comparisons and discrepancy between sample/gene numbers.









**SIGNAL STRENGTH VARIES IN  
TISSUE PROFILING EXPERIMENTS**

**THE MOST INTERESTING QUESTIONS  
TEND TO BE ASSOCIATED WITH  
WEAKER SIGNAL.**

CONSIDER A SAMPLE SET




CONSIDER A SAMPLE SET



THESE ARE EASY TO DISTINGUISH BY  
ONE MEASUREMENT PER INDIVIDUAL.

CONSIDER A SAMPLE SET


TUMORS



EXPRESSION LEVEL  
(HIGHLY INFORMATIVE GENE)


THESE ARE EASY TO DISTINGUISH BY  
ONE MEASUREMENT PER INDIVIDUAL.

CONSIDER A SAMPLE SET



THESE ARE HARDER TO DISTINGUISH. REQUIRE MORE THAN ONE MEASUREMENT PER INDIVIDUAL.


CONSIDER A SAMPLE SET



THESE ARE HARDER TO DISTINGUISH. REQUIRE MORE THAN ONE MEASUREMENT PER INDIVIDUAL.

CONSIDER A SAMPLE SET

TUMORS



EXPRESSION LEVEL  
(POORLY INFORMATIVE GENE)

THESE ARE HARDER TO DISTINGUISH. REQUIRE  
MORE THAN ONE MEASUREMENT PER INDIVIDUAL.

**WE CAN TELL APPLES  
FROM ORANGES.**

**CAN WE DISTINGUISH  
DIFFERENT KINDS OF APPLES?**

A CONTINUUM OF POSSIBLE OUTCOMES  
FROM MICROARRAY RESEARCH

- SOME FEATURES WILL SEPARATE TUMORS EASILY INTO CLASSES, AND MIGHT BE REDUCED TO SINGLE GENE TESTS, IMPLEMENTED IN A CONVENTIONAL FASHION.
- OTHERS WILL BE MORE DIFFICULT, AND REQUIRE MULTIPLE GENE MEASUREMENTS.
- MANY CLINICALLY RELEVANT FEATURES APPEAR TO FALL WITHIN THIS DIFFICULT GROUP.

A CONTINUUM OF POSSIBLE OUTCOMES  
FROM MICROARRAY RESEARCH

- SOME GENES WILL SHOW DIFFERENCES BETWEEN GROUPS OF SAMPLES BY CHANCE ALONE.
- THERE MAY BE NO ONE GENE WHICH SEPARATES GROUPS RELIABLY.
- FIND THE MOST INFORMATIVE GENES AND USE THEM IN COMBINATION .

**RISK OF OVERFITTING IN CLINICAL  
STUDIES WITH SMALL SAMPLE  
SETS**

**NEED INDEPENDENT VALIDATION  
SETS.**

**MICROARRAY STUDIES  
GENERATE ORGANIZED LIST OF GENES**


- **Often cryptic and hard to interpret.**
- **Hypothesis generating, but this is often rather subjective.**
- **Seldom provide strong evidence for a specific mechanism.**
- **Expression data is intrinsically limited.**

## GETTING BEYOND GENE LISTS

- Optimal use of gene annotations.
- Gene Ontology  
(<http://david.abcc.ncifcrf.gov/>)
- Optimizing use of public data.
  - GEO, ARRAY EXPRESS, ACADEMIC DATA
  - GENE SIGNATURE BASED METHODS (Gene Set Enrichment Analysis).

## GENE ONTOLOGY AND PROMOTER DATABASES CAN HELP FIND BIOLOGY

### GENE ONTOLOGY CATEGORIES AFFECTED BY ONCOGENE KNOCKDOWN IN EWING'S SARCOMA



KAUER ET AL. PLOS ONE 4:e5415 2009

## GETTING BEYOND GENE LISTS

- **Incorporating data from model systems.**
- **Linking expression data to sequence (e.g. Regulatory elements).**
- **Integrating other types of genome scale data.**





WHAT TO LOOK FOR IN CLINICAL  
CORRELATIVE STUDIES  
USING MICROARRAYS

- WELL DEFINED QUESTION AND PATIENT SAMPLE.
- HIGH QUALITY ARRAY MEASUREMENTS  
(HARD TO ASSESS WITHOUT REFERENCE TO  
PRIMARY DATA---SHOULD BE MADE PUBLIC).
- APPROPRIATE AND RIGOROUS STATISTICAL  
ANALYSIS OF ARRAY DATA.
- FORMAL CLASSIFIER THAT CAN BE APPLIED TO  
NEW SAMPLES.
- VALIDATION SAMPLE SET.

WHAT TO LOOK FOR IN CLINICAL  
CORRELATIVE STUDIES  
USING MICROARRAYS

- **GOAL SHOULD BE TO SEEK AND  
VALIDATE CLINICALLY RELEVANT  
SIGNATURES WITHIN DEFINED  
PATIENT GROUPS FOR WHICH NO  
CURRENT FEATURES ADEQUATELY  
ANSWER THE CLINICAL QUESTION  
POSED.**

## **EXPRESSION PROFILING IN THE CLINIC?**

### **PROBLEMS:**

- **SPECIALIZED TECHNOLOGY**
- **RNA IS UNSTABLE**
- **FROZEN TISSUE NOT PART OF USUAL OR SAMPLE FLOW**

## **EXPRESSION PROFILING IN THE CLINIC?**

### **OPTIONS:**


- **REFERENCE LABORATORIES**
- **RNA PRESERVATIVES**
- **USE OF PARAFFIN EMBEDDED MATERIALS.**

## EXPRESSION PROFILING IN THE CLINIC?

- **COMMERCIAL TESTS BEGINNING TO APPEAR.**
- **FDA IS ADDRESSING MULTIPLEX GENE EXPRESSION TESTS.**
- **LIMITED CLINICAL VALIDATION SO FAR**


## FDA APPROVED TESTS FOR BREAST CANCER BASED ON EXPRESSION STUDIES

### 70 GENE MICROARRAY SIGNATURE



Van de Vijver et al  
NEJM 347:1999 .

### Multigene RT-PCR Signature



Paik et al NEJM 351:2817

## ARRAYS VS. NEXT GENERATION SEQUENCING

- ARRAY TECHNOLOGIES MEASURE THE RELATIVE ABUNDANCE OF NUCLEIC ACIDS OF DEFINED SEQUENCE IN A COMPLEX MIXTURE.
- SEQUENCING CAN ACCOMPLISH THE SAME THING.

## ARRAYS VS. NEXT GENERATION SEQUENCING

### MICROARRAYS

- READILY AVAILABLE MATURE TECHNOLOGY
- RELATIVELY INEXPENSIVE
- EFFECTIVE WITH VERY COMPLEX SAMPLES
- HUNDREDS OF SAMPLES PRACTICAL
- CAN TARGET SUBSET OF GENOME

### SEQUENCING

- WHOLE GENOME DATA
- RELATIVELY UNIFORM ANALYTICAL PIPELINE
- FREE OF HYBRIDIZATION ARTIFACTS
- POSSIBILITY OF ONE PLATFORM FOR ALL APPLICATIONS

PROS

CONS

- REQUIRE PLATFORM AND APPLICATION SPECIFIC DATA PROCESSING
- PRONE TO PLATFORM SPECIFIC ARTIFACTS
- MANY SOURCES OF NOISE
- WHOLE GENOME STUDIES GENERALLY REQUIRE MANY ARRAYS, INCREASING SAMPLE REQUIREMENTS AND COMPLICATING ANALYSIS

- IMMATURE TECHNOLOGY
- HIGH COSTS
- COMPUTATIONALLY INTENSIVE
- LIMITED SAMPLE THROUGHPUT


MICROARRAYS


SEQUENCING

### MEASURING GENE EXPRESSION BY RNA SEQUENCING

- TAG SEQUENCING (SAGE-LIKE)
- FULL LENGTH mRNA----RNA-Seq
- 3' fragment mRNA sequencing
- miRNA sequencing

### MEASURING GENE EXPRESSION BY RNA SEQUENCING






### MEASURING GENE EXPRESSION BY RNA SEQUENCING: PROS AND CONS

#### ADVANTAGES



- RNA SEQUENCE VARIATIONS DETECTED AT SINGLE NUCLEOTIDE RESOLUTION
  - ALLELE SPECIFIC EXPRESSION
  - MUTATIONS
- RNA STRUCTURE: SPLICING, START SITES, TERMINATION SITES; REARRANGEMENTS
- DETECTED SIGNALS ARE RELATIVELY UNAMBIGUOUS; POTENTIAL TO OUTPERFORM MICROARRAY
- DE NOVO ASSEMBLY IS POSSIBLE




**MEASURING GENE EXPRESSION BY  
RNA SEQUENCING: PROS AND CONS**

**LIMITATIONS**

- **LOWER LIMIT OF DETECTION IS CONSTRAINED BY THE mRNA ABUNDANCE DISTRIBUTION AND THE NUMBER OF ALIGNED READS PER SAMPLE.**
- **LARGE SAMPLE NUMBERS DIFFICULT TO ACHIEVE, EXCEPT IN TAG MODE.**
- **SOFTWARE IS STILL DEVELOPMENTAL: REQUIRES SOPHISTICATED BIOINFORMATICS COLLABORATION. [For review see Pepke et al. Nat Methods 6:S22 (2009)]**







- ### 3' TAG SEQUENCING
- SEQUENCES ALIGNED AND COUNTED
  - LIBRARIES OF TAGS FROM MANY SAMPLES CAN BE IDENTIFIED BY ADDING A "BARCODE" AND POOLED BEFORE SEQUENCING
  - POTENTIAL TO ANALYZE LARGE NUMBERS OF SAMPLES IN PARALLEL

## THE FUTURE?

AS SEQUENCE THROUGHPUT INCREASES AND COSTS PER READ DECLINE, SEQUENCING IS LIKELY TO BECOME AN ATTRACTIVE ALTERNATIVE TO MICROARRAYS IN MORE AND MORE APPLICATIONS.

## USEFUL WEB SITES

**MGEGD The Microarray Gene Expression Data Society:**

<http://www.mged.org/>

**NCBI Gene Expression Omnibus:**

<http://ncbi.nih.gov/geo/>

**NCBI Sequence Read Archive (SRA):**

<http://www.ncbi.nlm.nih.gov/sra>

**EBI Microarray informatics:**

<http://www.ebi.ac.uk/microarray/index.html>

**Stanford Microarray Database:**

<http://smd.stanford.edu/>

**UCSF DeRisi lab:**

<http://derisilab.ucsf.edu/data/microarray/index.html>

**Broad Institute:**

**Gene Set Enrichment Analysis (GSEA)**

<http://www.broadinstitute.org/gsea/>

**Connectivity Map:**

<http://www.broadinstitute.org/cmap/>